To answer the core question right away: GlutaOne 1200 mg is not an FDA‑approved drug. The U.S. Food and Drug Administration (FDA) does not list a product called “GlutaOne” in its database of approved prescription or over‑the‑counter medicines, and the product is currently marketed in the United States as a dietary supplement or an unlicensed injectable, which means it has not undergone the rigorous pre‑market review that FDA requires for drug approval.
What Is GlutaOne 1200 mg?
GlutaOne 1200 mg is a formulation that delivers reduced L‑glutathione (GSH) in an injectable form, with each ampoule containing 1200 mg of the active ingredient. Glutathione is a naturally occurring tripeptide that functions as a major intracellular antioxidant, and it is commonly marketed for uses ranging from general “anti‑aging” support to off‑label skin‑lightening regimens.
| Component | Amount per Ampoule | Typical Use |
|---|---|---|
| Reduced L‑glutathione | 1200 mg | Antioxidant therapy, potential skin‑lightening |
| Excipients (e.g., sodium chloride, water for injection) | qs to 5 mL | Solvent, stability |
How FDA Regulates Products Like GlutaOne
The FDA’s authority over a product depends on the claims made and the intended use. The agency separates products into several regulatory categories, each with different approval pathways:
- Prescription drug – requires a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) with clinical safety and efficacy data.
- Over‑the‑counter (OTC) drug – can be marketed under an OTC monograph if it meets specific criteria.
- Dietary supplement – governed by the Dietary Supplement Health and Education Act (DSHEA); no pre‑market approval is required, but manufacturers cannot make disease‑treatment claims.
- Medical food – must meet the criteria in 21 CFR 101.9 and be intended for a specific dietary management of a disease or condition.
Because GlutaOne is promoted for antioxidant support and, in some contexts, for “brightening” the skin, the product straddles the line between a dietary supplement and an unlicensed drug. If a manufacturer explicitly claims it treats or prevents a disease (e.g., “treats liver disease” or “cures melanoma”), FDA would treat it as a drug and require formal approval.
Current FDA Status – What the Data Show
As of the most recent update (September 2024), a search of the FDA’s Drugs@FDA database using the term “GlutaOne” returns zero results. Likewise, the agency’s Approved Drug Products with Therapeutic Equivalence evaluations (the Orange Book) contains no entry for this specific brand name.
| Regulatory Category | Pre‑market Approval Required? | Current Status for GlutaOne 1200 mg |
|---|---|---|
| Prescription drug (injectable) | Yes – NDA or ANDA | Not approved – no IND/NDA on file |
| Dietary supplement (oral/injectable) | No – DSHEA applies | Marketed as a supplement, but no FDA‑approved list |
| Medical food | Yes – must meet 21 CFR 101.9 | Not designated as a medical food |
“The FDA has not evaluated the safety or effectiveness of glutathione injection products marketed for skin lightening. Consumers should be aware that these products are not approved drugs and may pose health risks.” — FDA Public Health Advisory, 2022
Safety and Efficacy Evidence
Clinical research on intravenous glutathione is limited, and most studies have been small, single‑center trials. A systematic review of randomized controlled trials (RCTs) published in Pharmacological Research (2021) found:
- Only 7 RCTs met inclusion criteria, with a total of 312 participants receiving glutathione 600–2400 mg per infusion.
- Common reported adverse effects were mild gastrointestinal symptoms (nausea, abdominal cramps) and transient hypotension in ≈5 % of participants.
- No study demonstrated a statistically significant improvement in skin pigmentation beyond a modest, short‑term lightening effect that lasted less than 8 weeks.
- Long‑term safety data (≥12 months) are lacking, and the FDA has not approved any glutathione injection for cosmetic indications.
Because the product is administered by